Aldosterone-Angiotensin II Ratio for Primary Hyperaldosteronism Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for primary hyperaldosteronism (PHA) face challenges due to interference from anti-hypertensive treatments and limited predictive power, leading to false positive and false negative results, and require complex and costly confirmation testing.
Innovation Solution
Measuring the aldosterone-to-angiotensin II ratio (AA2R) in biological samples, which is less prone to interference from anti-hypertensive treatments and provides improved diagnostic performance compared to the aldosterone-to-renin ratio (ARR) by offering higher discrimination between PHA and non-PHA patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the aldosterone-to-renin ratio (ARR) is used for diagnosis of primary hyperaldosteronism, then the diagnostic specificity and sensitivity can be improved compared to measuring aldosterone alone, but the diagnostic power remains insufficient leading to false positive and false negative results
Solution Approach 1:
The patent changes the diagnostic parameter from ARR (aldosterone-to-renin ratio) to AAR (aldosterone-to-angiotensin II ratio). This parameter substitution resolves the contradiction by using angiotensin II levels instead of renin levels, providing both improved measurement precision and diagnostic reliability for detecting primary hyperaldosteronism.
2Measurement precision
If confirmation testing is performed to improve diagnostic accuracy, then false results can be reduced, but the testing protocol becomes complex and costly
Solution Approach 1:
The patent merges the screening and confirmation functions into a single AAR measurement. By combining these functions that were previously separate, the testing protocol becomes simpler and less costly while maintaining high diagnostic accuracy, thus resolving the contradiction between diagnostic precision and protocol complexity.
3Reliability
If anti-hypertensive treatments are administered to patients, then blood pressure control is improved, but the diagnostic power of ARR is interfered with leading to false results
Solution Approach 1:
The patent uses angiotensin II as an intermediary parameter that is less affected by anti-hypertensive medications compared to renin. This intermediary approach allows diagnostic measurement to proceed accurately even when patients are on blood pressure medication, resolving the contradiction between blood pressure control and diagnostic precision.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.